Kinetic studies of lipoprotein metabolism in the metabolic syndrome including effects of nutritional interventions

Current Opinion in Lipidology

Volumn 14, Issue 1, 2003, Pages 61-68

  Hugh, P ^a,b   Barrett, R ^a   Watts, Gerald F ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Apolipoproteins; Dyslipoproteinemia; Kinetics; Lipoproteins; Metabolism; Tracers

Indexed keywords

APOLIPOPROTEIN; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OMEGA 3 FATTY ACID; PHYTOSTEROL; STATIN; VERY LOW DENSITY LIPOPROTEIN;

CALORIC INTAKE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIET SUPPLEMENTATION; DYSLIPOPROTEINEMIA; ENVIRONMENTAL FACTOR; ENZYME KINETICS; HUMAN; INSULIN RESISTANCE; LIPOPROTEIN METABOLISM; METABOLIC SYNDROME X; NUTRITIONAL STATUS; PRIORITY JOURNAL; REVIEW; WEIGHT REDUCTION;

ALCOHOLS; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS; METABOLIC SYNDROME X; NUTRITION PHYSIOLOGY; STEROLS;

EID: 0037317672     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200302000-00011     Document Type: Review

References (71)

1. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third national health and nutrition examination survey. JAMA 2002; 287:356-359.
2. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106:453-458.
3. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15:539-553.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). JAMA 2001; 285:2486-2497.
5. Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation 1996; 94:273-278.
6. Turner RC, Millns H, Neil HAW, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998; 316:823-828.
7. McNamara DJ. Effects of fat-modified diets on cholesterol and lipid metabolism. Ann Rev Nutr 1987; 7:273-290.
8. Grundy SM, Denke MA. Dietary influences on serum lipids and lipoproteins. J Lipid Res 1990; 31:1149-1172.
9. Schaefer E.J. Lipoproteins, nutrition, and heart disease. Am J Clin Nutr 2002; 75:191-212. This is a significant review of the literature that focuses on lipoproteins and nutrition in relation to heart disease. The review discusses dietary intervention studies, diet-gene interactions and dietary guidelines.
10. Marsh JB, Welty FK, Lichtenstein AH, et al. Apolipoprotein B metabolism in humans: studies with staple isotope-labeled amino acid precursors. Atherosclerosis 2002; 162:227-244. This is a comprehensive review of apoB kinetic studies employing stable isotope tracers. Included in this review are discussions of experimental methodologies and methods of data analysis. In addition, studies examining the effects of aging, diet, dyslipidemias, hormones and statins upon apoB metabolism are presented.
11. Marsh JB, Welty FK, Schaefer EJ. Stable isotope turnover of apolipoproteins of high-density lipoproteins in humans. Curr Opin Lipidol 2000; 22:261-266.
12. Barrett PHR, Foster DM. Design and analysis of lipid tracer kinetic studies. Curr Opin Lipidol 1996; 7:143-148.
13. Dwyer K, Barrett PHR, Chan D, et al. Oxazolinone derivatives of amino acids and gas chromatography-mass spectrometry: femtogram sensitivity applied to stable isotope kinetic studies of lipoproteins. J Lipid Res 2002; 43:344-349. This describes the development of a new derivative for measurement of stable isotope enrichment in amino acids. The oxazolinone derivative is highly stable and sensitive because of its small size and low natural stable isotope abundance.
14. Burnett JR, Barrett PHR. Apolipoprotein B metabolism: tracer kinetics, models, and metabolic studies. Crit Rev Clin Lab Sci 2002; 39:89-137. This review focuses on the role of apoB in lipoprotein metabolism and explores the application of kinetic analysis and compartmental modelling to kinetic studies of apoB metabolism. The application of compartment models to cell culture studies, animals and human studies is also reviewed.
15. Patterson BW. Methods for measuring lipid metabolism in vivo. Curr Opin Clin Nutr Metab Care 2002; 5:475-479.
16. Barrett PHR, Baker N, Nestel PJ. Model development to describe the heterogeneous kinetics of apolipoprotein B and triglyceride in hypertriglyceridemic subjects. J Lipid Res 1991; 32:743-762.
17. Fisher WR, Venkatakrishnan V, Zech LA, et al. Kinetic evidence for both a fast and a slow secretory pathway for apolipoprotein A-I in humans. J Lipid Res 1995; 36:1618-1628.
18. Berman M, Hall M, Levy RI, et al. Metabolism of apoB and apoC lipoproteins in man: kinetic studies in normal and hyperlipoproteinemic subjects. J Lipid Res 1978; 19:38-56.
19. Packard CJ, Gaw A, Demant T, Shepherd J. Development and application of a multicompartmental model to study very low density lipoprotein subfraction metabolism. J Lipid Res 1995; 36:172-187.
20. Riches FM, Watts GF, Naoumova RP, et al. Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity. Int J Obes Relat Metab Disord 1998; 22:414-423.
21. Chan DC, Watts GF, Mori TA, et al. Randomized controlled trial of the effect of n-3 fatty acids supplementation on apolipoprotein B-100 and chylomicron remnant metabolism in visceral obesity. Am J Clin Nutr (in press).
22. Watts GF, Chan DCF, Barrett PHR, et al. Preliminary experience with a stable isotope breath test for chylomicron remnant metabolism: a study in central obesity. Clin Sci 2001; 101:683-690.
23. Chan DC, Watts GF, Barrett PHR, et al. Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity. Clin Chem 2002; 48:278-283.
24. Chan D, Watts GF, Redgrave TG, et al. Apolipoprotein B100 kinetics in visceral obesity: associations with plasma apolipoprotein CIII concentrations. Metabolism 2002; 51:1041-1046. Plasma lipid and lipoprotein abnormalities observed in visceral obesity are due to a combination of over secretion and impaired catabolism. This study demonstrated a strong positive association between VLDL apoB secretion and apoCIII concentration. This association remained after adjusting for insulin resistance, free fatty acids and cholesterol synthesis. VLDL apoB FCR was inversely associated with apoCIII.
25. Watts GF, Chan DC, Susekov A, Barrett PHR. Adipose tissue compartments and the kinetics of very-low-density-lipoprotein B-100 in overweight-obese men. Obes Res (in press).
26. Riches FM, Watts GF, van Bockxmeer FM, et al. Apolipoprotein B signal peptide and apolipoprotein E genotypes as determinants of the hepatic secretion of VLDL apoB in obese men. J Lipid Res 1998; 39:1752-1758.
27. Watts GF, Riches FM, Humphries SE, et al. Genotypic associations of the hepatic secretion of VLDL apolipoprotein B-100 in obesity. J Lipid Res 2000; 41:481-488.
28. Duvillard L, Pont F, Florentin E, et al. Inefficiency of insulin therapy to correct apolipoprotein A-I metabolic abnormalities in non-insulin-dependent diabetes mellitus. Atherosclerosis 2000; 152:229-237.
29. Pietzsch J, Julius U, Nitzsche S, Hanefeld M. In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. Diabetes 1998; 47:1928-1934.
30. Watts GF, Barrett PHR, Serone AP, et al. Differential regulation of lipoprotein metabolism by atorvastatin and fenofibrate. Atherosclerosis 2002; 3:235S [abstract].
31. Lamarche B, Uffelman KD, Carpentier A, et al. Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J Clin Invest 1999; 103:1191-1199.
32. Riches FM, Watts GF, Hua J, et al. Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men. J Clin Endocrinol Metab 1999; 84:2854-2861.
33. Nestel PJ. Fish oil and cardiovascular disease: lipids and arterial function. Am J Clin Nutr 2000; 71:228S-231S.
34. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989; 2:757-761.
35. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI Prevenzione trial. Lancet 1999; 354:447-455.
36. Nestel PJ, Connor WE, Reardon MF, et al. Suppression by diets rich in fish oil of very low density lipoprotein production in man. J Clin Invest 1984; 74:82-89.
37. Bordin P, Bodamer OA, Venkatesan S, et al. Effects of fish oil supplementation on apolipoprotein B 100 production and lipoprotein metabolism in normolipidemic males. Eur J Clin Nutr 1998; 52:104-109.
38. 3-leucine. A compartment model was used for the analysis of the tracer data. Fish oil reduced VLDL apoB secretion and the conversion of VLDL to LDL. Atorvastatin increased VLDL, IDL and LDL fractional catabolic rates with no effect of apoB secretion. Combined therapy produced additive affects on plasma triglycerides, HDL cholesterol, and VLDL apoB.
39. Chan D, Watts GF, Mori TA, et al. Factorial study of the effects of atorvastatin and fish oil on dyslipidemia in visceral obesity. Eur J Clin Invest 2002; 32:429-436.
40. Chan DC, Watts GF, Barrett PHR, et al. Mechanism of action of an HMG CoA reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity. J Clin Endocrinol Metab 2002; 87:2283-2289.
41. Mori TA, Watts GF, Burke V, et al. Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men. Circulation 2000; 102:1264-1269.
42. Mori TA, Burke V, Puddey IB, et al. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipoproteins, LDL particle size, glucose and insulin in mildly hyperlipidemic men. Am J Clin Nutr 2000; 71: 1085-1094.
43. Von Eckardstein A, Nofer J-R, Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001; 21:13-27.
44. Frenais R, Ouguerram K, Maugeais C, et al. Effect of dietary omega-3 fatty acids on high-density lipoprotein apolipoprotein AI kinetics in type II diabetes mellitus. Atherosclerosis 2001; 157:131-135.
45. Huggins KW, Colvin PL, Burleson ER, et al. Dietary n-3 polyunsaturated fat increases the fractional catabolic rate of medium-sized HDL particles in African green monkeys. J Lipid Res 2001; 42:1457-1466.
46. Montoya MT, Porres A, Serrano S, et al. Fatty acid saturation of the diet and plasma lipid concentrations, lipoprotein particte concentrations, and cholesterol efflux capacity. Am J Ciin Nutr 2002; 75:484-491.
47. Torra IP, Chinetti G, Duval C, et al. Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice. Curr Opin Lipidol 2001; 12:245-254.
48. Velez-Carrasco W, Lichtenstein AH, Welty FK, et al. Dietary restriction of saturated fat and cholesterol decreases HDL ApoA-I secretion. Arterioscler Thromb Vasc Biol 1999; 19:918-924.
49. Miettinen TA, Gylling H. Regulation of cholesterol metabolism by dietary plant sterols. Curr Opin Lipidol 1999; 10:9-14.
50. Thompson GR, Naoumova RP, Watts GF. Role of cholesterol in regulating apolipoprotein B metabolism by the liver. J Lipid Res 1996; 37:439-447.
51. Gylling H, Miettinen TA. Serum cholesterol and lipoprotein metabolism in hypercholesterolaemic patients before and during sitostanol ester-margarine treatment. Diabetologia 1994; 37:773-780.
52. Gylling H, Miettinen TA. Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterolemic non-insulin-dependent diabetic men. J Lipid Res 1996; 37:1776-1785.
53. Simonen P, Gylling H, Miettinen TA. Body weight modulates cholesterol metabolism in non-insulin dependent type 2 diabetes. Obes Res 2002; 10:328-335. Following on from their previous studies [54] suggesting that low cholesterol absorption and high synthesis may be part of the metabolic syndrome, this study reports on the association between insulin resistance, cholesterol synthesis and cholesterol absorption. With increasing insulin resistance, cholesterol synthesis rises and the absorption of cholesterol falls.
54. Simonen P, Gylling H, Howard An, Miettinen TA. Introducing a new component of the metabolic syndrome: low cholesterol absorption. Am J Clin Nutr 2000; 72:82-88.
55. Watts GF, Chan DC, Barrett PHR, et al. Effects of HMGCoA reductase inhibitor on cholesterol absorption in obesity: implications for the regulation of very-low-density lipoprotein B-100 metabolism. Atherosclerosis 2002; 3:235S [abstract].
56. Simons LA. Additive effect of plant-sterol ester margarine and cerivastatin in lowering low-density lipoprotein cholesterol in primary hypercholesterolemia. Am J Cardiol 2002; 90:737-740. A multicentre, randomized trial with four parallel treatment arms on the effects of plant sterols (2 g) and cerivastatin (400 μg) treatment in hypercholesterolemic subjects. Sterol and statin reduced LDL cholesterol concentrations 8 and 32%, respectively. Sterol plus statin treatment demonstrated additive effects with a 39% reduction in LDL cholesterol.
57. Gylling H, Miettinen TA. Inheritance of cholesterol metabolism of probands with high or low cholesterol absorption. J Lipid Res 2002; 43:1472-1476. Cholesterol absorption studied in siblings of hypercholesterolemic patients revealed a significant heritable component. Cholesterol absorption was measured as the ratio of plant sterols to plasma cholesterol. Cholesterol synthesis was also estimated from the measurement of plasma cholesterol precursors.
58. Berge KE, von Bergmann K, Lutjohann D, et al. Heritability of plasma noncholesterol sterols and relationship to DNA sequence polymorphism in ABCG5 and ABCG8. J Lipid Res 2002; 43:486-494
59. Rimm EB, Giovannucci EI, Willett WC, et al. Prospective study of alcohol consumption and risk of coronary disease in men. Lancet 1992; 338:464-468.
60. Pearson TA. Alcohol and heart disease. Circulation 1996; 94:3023-3025.
61. Malmendier CL, Delcroix C. Effect of alcohol intake on high and low density lipoprotein metabolism in healthy volunteers. Clin Chim Acta 1985; 152:281-288.
62. Gottrand F, Beghin L, Duhal N, et al. Moderate red wine consumption in healthy volunteers reduced plasma clearance of apolipoprotein All. Eur J Clin Invest 1999; 29:387-394.
63. De Oliveira e Sliva ER, Foster DM, Harper MM, et al. Alcohol consumption raises HDL cholesterol levels by increasing the transport rate of apolipoproreins AI and AII. Circulation 2000; 102:2347-2352.
64. Dashti N, Franklin FA, Abrahamson DR. Effect of ethanol on the synthesis and secretion of apoAI and apoB-containing lipoprotein in HepG2 cells. J Lipid Res 1996; 37: 810-824.
65. Hagiage M, Marti C, Rigaud D, et al. Effect of a moderate alcohol intake on the lipoproteins of normotriglyceridemic obese subjects compared with normoponderal controls. Metabolism 1992; 41:856-861.
66. Fumeron F, Betoulle D, Luc G, et al. Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction. J Clin Invest 1995; 96:1664-1671.
67. Patterson BW, Mittendorfer B, Elias N, et al. Use of stable isotopically labelled tracers to measure very low density lipoprotein-triglyceride turnover. J Lipid Res 2002; 43:223-233.
68. Redgrave TG, Watts GF, Martins IJ, et al. Chylomicron remnant metabolism in familial dyslipidemias studied with a remnant-like emulsion breath test. J Lipid Res 2001; 42:710-715.
69. Ouguerram K, Krempf M, Maugeais C, et al. A new labelling approach using stable isotopes to study in vivo plasma cholesterol metabolism in humans. Metabolism 2002; 51:5-11.
70. Chetiveaux M, Nazih H, Ferchaud-Roucher V, et al. The differential apoA-I enrichment of preβ1 and αHDL is detectable by gel filtration separation. J Lipid Res 2002; 43:1986-1993.
71. Bosner MS, Lange LG, Stenson WF, Ostlund RE. Percent cholesterol absorption in normal women and men quantified with dual stable isotope tracers and negative ion mass spectrometry. J Lipid Res 1999; 40:302-308.